FDA Approves New Drug for Resistant Lung Cancer Patients

Adults with a rare form of lung cancer now have a new treatment option after their disease stops responding to initial therapies.

The FDA just approved zidesamtinib for patients with ROS1-positive lung cancer who've already tried one targeted treatment.